| Issue Date | Title | Author(s) |
| 1 | 2012 | Cumulative clinical experience from a decade of use: imatinib as first-line treatment of chronic myeloid leukemia | Baran, Yusuf ; Saydam, Güray |
| 2 | Jul-2011 | Effect of cobalt-60 (? radiation) on multidrug-resistant multiple myeloma cell lines | Mutlu, Pelin; Baran, Yusuf ; Ural, Ali Ugur; Avcu, Ferit; Dirican, Bahar; Beyzadeoglu, Murat; Gündüz, Ufuk |
| 3 | Mar-2018 | Environmentally responsive dual-targeting nanoparticles: Improving drug accumulation in cancer cells as a way of preventing anticancer drug efflux | Dağlıoğlu, Cenk |
| 4 | 2023 | Epithelial-mesenchymal transition as a potential route for DAPT resistance in breast cancer cells | Telli, Kübra; Yalçın Özuysal, Özden |
| 5 | 2019 | Genomewide elucidation of drug resistance mechanisms for systemically used antifungal drugs amphotericin B, caspofungin, and voriconazole in the budding yeast | Balkan, Çiğdem; Ercan, İlkcan; Işık, Esin; Akdeniz, Esra Şahin ; Balcıoğlu, Orhan; Kodedova, Marie; Koç, Ahmet |
| 6 | Apr-2013 | miR-17 in imatinib resistance and response to tyrosine kinase inhibitors in chronic myeloid leukemia cells | Fıratlıgil, Burcu ; Biray Avcı, Çığır; Baran, Yusuf |
| 7 | 2014 | Multidrug resistance in chronic myeloid leukemia | Ünlü, Miray ; Kiraz, Yağmur ; Kacı, Fatma Necmiye; Özcan, Mehmet Ali; Baran, Yusuf |
| 8 | Feb-2010 | Nilotinib significantly induces apoptosis in imatinib resistant K562 cells with wild-type BCR-ABL, as effectively as in parental sensitive counterparts | Ekiz, Hüseyin Atakan ; Can, Geylani; Gündüz, Ufuk; Baran, Yusuf |
| 9 | Jan-2013 | Novel agents targeting bioactive sphingolipids for the treatment of cancer | Adan Gökbulut, Aysun ; Kartal Yandım, Melis; İskender, Güniz; Baran, Yusuf |
| 10 | 2019 | The role of cysteine cathepsins in cancer progression and drug resistance | Rudzinska, Magdalena; Parodi, Alessandro; Soond, Surinder M.; Vinarov, Andrey Z.; Korolev, Dmitry O.; Morozov, Andrey O.; Zamyatnin, Andrey A., Jr.; Dağlıoğlu, Cenk ; Tutar, Yusuf |
| 11 | Jun-2011 | Sphingosine kinase-1 and sphingosine 1-phosphate receptor 2 mediate Bcr-Abl1 stability and drug resistance by modulation of protein phosphatase 2A | Salas, Arelis; Ponnusamy, Suriyan; Senkal, Can E.; Meyers-Needham, Marisa; Selvam, Shanmugam Panneer; Saddoughi, Sahar A.; Apohan, Elif; Sentelle, R. David; Smith, Charles; Gault, Christopher R.; Obeid, Lina M.; El-Shewy, Hesham M.; Oaks, Joshua; Santhanam, Ramasamy; Marcucci, Guido; Baran, Yusuf ; Mahajan, Sandeep; Fernandes, Daniel; Stuart, Robert; Perrotti, Danilo; Öğretmen, Besim |
| 12 | Oct-2011 | Targeting glucosylceramide synthase sensitizes imatinib-resistant chronic myeloid leukemia cells via endogenous ceramide accumulation | Baran, Yusuf ; Bielawski, Jacek; Gündüz, Ufuk; Öğretmen, Besim |
| 13 | Oct-2010 | Therapeutic applications of bioactive sphingolipids in hematological malignancies | Ekiz, Hüseyin Atakan ; Baran, Yusuf |
| 14 | Jan-2013 | Therapeutic potential of targeting ceramide/glucosylceramide pathway in cancer | Kartal Yandım, Melis; Apohan, Elif; Baran, Yusuf |
| 15 | Dec-2015 | An update on molecular biology and drug resistance mechanisms of multiple myeloma | Mutlu, Pelin; Kiraz, Yağmur ; Gündüz, Ufuk; Baran, Yusuf |
